Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

Ruriko Tanaka, Shinya Kimura, Eishi Ashihara, Mariko Yoshimura, Naoto Takahashi, Hisashi Wakita, Kuniaki Itoh, Kaichi Nishiwaki, Kenshi Suzuki, Rina Nagao, Hisayuki Yao, Yoshihiro Hayashi, Sakiko Satake, Hideyo Hirai, Ken ichi Sawada, Oliver G. Ottmann, Junia V. Melo, Taira Maekawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalCancer Letters
Volume312
Issue number2
DOIs
Publication statusPublished - Dec 22 2011
Externally publishedYes

Fingerprint

Phosphotransferases
Mutation
Protein-Tyrosine Kinases
Polymerase Chain Reaction
Guanine
Leukemia
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tanaka, R., Kimura, S., Ashihara, E., Yoshimura, M., Takahashi, N., Wakita, H., ... Maekawa, T. (2011). Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Letters, 312(2), 228-234. https://doi.org/10.1016/j.canlet.2011.08.009

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. / Tanaka, Ruriko; Kimura, Shinya; Ashihara, Eishi; Yoshimura, Mariko; Takahashi, Naoto; Wakita, Hisashi; Itoh, Kuniaki; Nishiwaki, Kaichi; Suzuki, Kenshi; Nagao, Rina; Yao, Hisayuki; Hayashi, Yoshihiro; Satake, Sakiko; Hirai, Hideyo; Sawada, Ken ichi; Ottmann, Oliver G.; Melo, Junia V.; Maekawa, Taira.

In: Cancer Letters, Vol. 312, No. 2, 22.12.2011, p. 228-234.

Research output: Contribution to journalArticle

Tanaka, R, Kimura, S, Ashihara, E, Yoshimura, M, Takahashi, N, Wakita, H, Itoh, K, Nishiwaki, K, Suzuki, K, Nagao, R, Yao, H, Hayashi, Y, Satake, S, Hirai, H, Sawada, KI, Ottmann, OG, Melo, JV & Maekawa, T 2011, 'Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients', Cancer Letters, vol. 312, no. 2, pp. 228-234. https://doi.org/10.1016/j.canlet.2011.08.009
Tanaka R, Kimura S, Ashihara E, Yoshimura M, Takahashi N, Wakita H et al. Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Letters. 2011 Dec 22;312(2):228-234. https://doi.org/10.1016/j.canlet.2011.08.009
Tanaka, Ruriko ; Kimura, Shinya ; Ashihara, Eishi ; Yoshimura, Mariko ; Takahashi, Naoto ; Wakita, Hisashi ; Itoh, Kuniaki ; Nishiwaki, Kaichi ; Suzuki, Kenshi ; Nagao, Rina ; Yao, Hisayuki ; Hayashi, Yoshihiro ; Satake, Sakiko ; Hirai, Hideyo ; Sawada, Ken ichi ; Ottmann, Oliver G. ; Melo, Junia V. ; Maekawa, Taira. / Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. In: Cancer Letters. 2011 ; Vol. 312, No. 2. pp. 228-234.
@article{ab9a3eee65a9488fbe293289c8c454a0,
title = "Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients",
abstract = "ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.",
author = "Ruriko Tanaka and Shinya Kimura and Eishi Ashihara and Mariko Yoshimura and Naoto Takahashi and Hisashi Wakita and Kuniaki Itoh and Kaichi Nishiwaki and Kenshi Suzuki and Rina Nagao and Hisayuki Yao and Yoshihiro Hayashi and Sakiko Satake and Hideyo Hirai and Sawada, {Ken ichi} and Ottmann, {Oliver G.} and Melo, {Junia V.} and Taira Maekawa",
year = "2011",
month = "12",
day = "22",
doi = "10.1016/j.canlet.2011.08.009",
language = "English",
volume = "312",
pages = "228--234",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

AU - Tanaka, Ruriko

AU - Kimura, Shinya

AU - Ashihara, Eishi

AU - Yoshimura, Mariko

AU - Takahashi, Naoto

AU - Wakita, Hisashi

AU - Itoh, Kuniaki

AU - Nishiwaki, Kaichi

AU - Suzuki, Kenshi

AU - Nagao, Rina

AU - Yao, Hisayuki

AU - Hayashi, Yoshihiro

AU - Satake, Sakiko

AU - Hirai, Hideyo

AU - Sawada, Ken ichi

AU - Ottmann, Oliver G.

AU - Melo, Junia V.

AU - Maekawa, Taira

PY - 2011/12/22

Y1 - 2011/12/22

N2 - ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

AB - ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=80053987395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053987395&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2011.08.009

DO - 10.1016/j.canlet.2011.08.009

M3 - Article

C2 - 21890264

AN - SCOPUS:80053987395

VL - 312

SP - 228

EP - 234

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -